Through analysis of tumor samples from over 1200 patients, we demonstrated that low SPDEF levels were linked with worse survival across breast cancers, with the most profound changes seen in Basal tumors, younger patients, and Black or African American patients. This evidence concerns the gene SPDEF and neoplasm.